Every material Form 8-K Corcept Therapeutics filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Corcept Therapeutics reported third quarter 2026 revenue of $340.5 million, up 64 percent from the same period in 2025, and net income of $126.8 million, compared with $19.7 million a year earlier. The company reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, and its Lifyorli ovarian cancer product contributed $91.4 million of the quarter's revenue.
Q3 2026 revenue of $340.5 million vs. $207.6 million in Q3 2025; Korlym and authorized generic revenue was $249.1 million and Lifyorli revenue was $91.4 million
Q3 2026 net income of $126.8 million, or $1.01 per diluted share, vs. $19.7 million, or $0.16 per diluted share, in Q3 2025
2026 revenue guidance of $1.1 billion to $1.2 billion reiterated; cash and investments rose to $662.3 million at September 30, 2026
Relacorilant for Cushing's syndrome has a PDUFA date of December 17, 2026
Corcept Therapeutics said Sean Maduck, President of its Endocrinology division, will retire effective October 1, 2026, and Justin Gunn will succeed him. Maduck will stay on as a consultant under an agreement paying $57,000 per month, and the company said he did not resign because of any disagreement with the company. The filing does not include financial results or guidance changes, so the direct effect on shareholders is limited to the leadership change.
Sean Maduck notified the board on September 22, 2026 of his decision to resign effective October 1, 2026.
Maduck's consulting agreement runs through September 30, 2027, with a cash fee of $57,000 per month, and his outstanding stock options continue to vest.
Justin Gunn joined Corcept in July 2024 as Vice President of Sales and Commercial Learning for the Oncology division and will report to CEO Joseph K. Belanoff, M.D.
Corcept Therapeutics reported second-quarter 2026 revenue of $256.1 million, up 32% from $194.4 million a year earlier, and raised its 2026 revenue guidance to $1.1-$1.2 billion. Net income rose to $43.0 million from $35.1 million, though operating expenses increased to $214.8 million from $167.8 million on Lifyorli launch spending and Cushing's syndrome investments.
Q2 2026 revenue of $256.1 million, including $47.6 million from Lifyorli in its first quarter of availability
Diluted net income per share of $0.36, compared with $0.29 in Q2 2025
Operating expenses rose to $214.8 million from $167.8 million, driven by Lifyorli launch and Cushing's investments
Six-month net income was $11.2 million, down from $55.7 million a year earlier; the FDA decision on the Cushing's NDA is expected by December 17, 2026
At its May 21, 2026 annual meeting, Corcept Therapeutics stockholders approved an amendment adding 8,000,000 shares to the 2024 Incentive Award Plan, which took effect that day. The filing also reports the election of eight directors and the ratification of Ernst & Young LLP as the independent auditor for fiscal 2026. The plan increase expands the shares available for equity awards, which can dilute existing holders.
Stockholders approved the Amended 2024 Incentive Award Plan, adding 8,000,000 shares, with 53,163,364 votes for, 23,867,363 against and 263,730 abstaining.
All eight director nominees were elected to serve until the 2027 annual meeting, including Joseph K. Belanoff, M.D., and David L. Mahoney.
Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026, with 92,656,473 votes for.
In an advisory vote, stockholders approved named executive officer compensation, with 72,511,429 votes for and 4,560,385 against.
Corcept reported first quarter 2026 revenue of $164.9 million, up from $157.2 million a year earlier, but swung to a net loss of $31.8 million from net income of $20.5 million, as operating expenses rose to $214.5 million from $153.8 million. The company raised its 2026 revenue guidance to $950 million to $1,050 million and said it expects to return to profitability in the second quarter of 2026.
Revenue was $164.9 million versus $157.2 million in Q1 2025; diluted net loss per share was $0.30 versus diluted earnings of $0.17.
Operating expenses were $214.5 million versus $153.8 million, driven by spending to prepare for the Lifyorli launch and growth initiatives in the Cushing's syndrome business.
2026 revenue guidance was increased to $950 million to $1,050 million.
Cash and investments were $515.4 million at March 31, 2026, down from $532.4 million at December 31, 2025.
Corcept reported fourth quarter and full-year 2025 results with revenue up from 2024 but net income and diluted earnings per share down. The company also gave 2026 revenue guidance of $900 million to $1,000 million, and said its Cushing's syndrome business was constrained by specialty pharmacy capacity and a fourth-quarter pharmacy transition.
Full-year 2025 revenue was $761.4 million, up from $675.0 million in 2024.
Full-year 2025 net income was $99.7 million, or $0.82 diluted per share, down from $141.2 million, or $1.23 diluted per share, in 2024.
Fourth-quarter 2025 revenue was $202.1 million, up from $181.9 million; fourth-quarter net income was $24.3 million, or $0.20 diluted per share, down from $30.7 million, or $0.26.
Full-year 2026 revenue guidance is $900 million to $1,000 million; cash and investments were $532.4 million at December 31, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Corcept Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →